Drugs / BAY86-9596

Trials 2

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01297088 May → Dec 2011 — Lantheus Biosciences Ltd. Completed No outcome recorded
Phase 1 NCT01089998 May 2010 → Sep 2011 — Lantheus Biosciences Ltd. Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BAY86-9596 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01089998 ↗
1

NCT01297088 ↗

Known as (18f)d-fmt ChEMBL registry synonym — accepted as the source's own label CHEMBL4302826 ↗
Known as (d)-18f-fluoromethyltyrosine ChEMBL registry synonym — accepted as the source's own label CHEMBL4302826 ↗
Known as (f18)-d-fmt ChEMBL registry synonym — accepted as the source's own label CHEMBL4302826 ↗
Known as BAY-86-9596 F-18 ChEMBL registry synonym — accepted as the source's own label CHEMBL4302826 ↗
Known as D-(18f)fmt ChEMBL registry synonym — accepted as the source's own label CHEMBL4302826 ↗
Known as D-FLUOROMETHYLTYROSINE F-18 ChEMBL registry synonym — accepted as the source's own label CHEMBL4302826 ↗
Known as J2.566.882K ChEMBL registry synonym — accepted as the source's own label CHEMBL4302826 ↗
Modality Diagnostic / imaging agent “18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596” NCT01089998 ↗
Route Intravenous “single intravenous injection of BAY86-9596” NCT01089998 ↗